Table 1.

Rate of discontinuation of three tumor necrosis factor antagonists; reasons for discontinuation and rank of treatment

TNF antagonist	Reason for discontinuation	Rate per 100 patient years exposed
		First treatment	Second treatment
Infliximab	Adverse events	6.5	32.7
	Lack of efficacy	4.7	38.5
Etanercept	Adverse events	3.8	6.1
	Lack of efficacy	3.6	9.3
Adalimumab	Adverse events	7.2	12.5
	Lack of efficacy	3.2	12.5

TNF, tumor necrosis factor.